Search

Your search keyword '"Aragri A."' showing total 26 results

Search Constraints

Start Over You searched for: Author "Aragri A." Remove constraint Author: "Aragri A." Publisher elsevier ltd Remove constraint Publisher: elsevier ltd
26 results on '"Aragri A."'

Search Results

1. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome

3. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C

4. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

5. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance

6. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

8. Key mutations in HBsAg C-terminus correlate with lower HBsAg levels in vivo, hinder HBsAg release in vitro and affect HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection

9. National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing

10. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy

11. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life

12. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy

13. Natural HCV resistance is common in Italy and differently associated to genotypes

14. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies

15. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life

16. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network

17. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment

18. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents

21. Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors

22. Slow achievement of HCV-RNA undetectability in cirrhotic patients treated with sofosbuvir + ribavirin: possible clinical implications in the liver transplant list management

23. Key genetic markers in the full-length HBsAg gene correlate with HBV-driven carcinogenesis by affecting HBsAg secretion and release

24. Early viral dynamics in HCV-RNA decay and NS3-resistance development predict the risk of failure to first-generation protease inhibitors

25. Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?

Catalog

Books, media, physical & digital resources